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Abstract
Analyzing sequencing data is difficult because of the low frequency of rare variants, which may result in low power
to detect associations. We consider pathway analysis to detect multiple common and rare variants jointly and to
investigate whether analysis at the pathway level provides an alternative strategy for identifying susceptibility
genes. Available pathway analysis methods for data from genome-wide association studies might not be efficient
because these methods are designed to detect common variants. Here, we investigate the performance of several
existing pathway analysis methods for sequencing data. In particular, we consider the global test, which does not
consider linkage disequilibrium between the variants in a gene. We improve the performance of the global test by
assigning larger weights to rare variants, as proposed in the weighted-sum approach. Our conclusion is that
straightforward application of pathway analysis is not satisfactory; hence, when common and rare variants are
jointly analyzed, larger weights should be assigned to rare variants.
Background
Genome-wide association studies (GWAS) have found
hundreds of single-nucleotide polymorphisms (SNPs)
that are significantly associated with several complex
traits. In most cases, however, these SNPs explain only a
small proportion of the known genetic variance. A pos-
sible explanation is that causal variants have a lower
minor allele frequency (MAF) than common SNPs.
Moreover, rare variants are weakly correlated with com-
mon SNPs, because MAFs must be similar for two var-
iants to be highly correlated [1]. It follows that common
variants may have only a limited capacity to tag rare
variants. This limitation in GWAS, in which common
variants with a frequency of 5% or higher were used,
leads to a direct search for associations with multiple
rare variants. Recently, efforts have been made to geno-
type rare variants, such as in the 1000 Genomes Project
(http://www.1000genomes.org). The low frequency of
rare variants, however, may result in low power to
detect associations. Given currently available sample
sizes, there is a need for powerful methods to detect
association with multiple rare variants. We investigate
whether pooling variants by pathway into a composite
test provides an alternative strategy for identifying sus-
ceptibility genes.
Pathway analysis methods have been developed in the
context of gene expression data analysis. There are two
general approaches: competitive and self-contained. The
distinction lies in the definition of the null hypothesis and
in the calculation of the P-value [2,3]. Concerning the defi-
nition of the null hypothesis, a competitive test compares
differential expression of the gene set to a standard defined
by the complement of that gene set. In contrast, a self-
contained test compares the gene set to a fixed standard
that does not depend on the measurements of genes out-
side the gene set. Concerning the calculation of the
P-value, the competitive test bases the calculation of
the P-value for the gene set on a distribution in which the
gene is the sampling unit, whereas the self-contained test
takes the subject as the sampling unit.
Recently, these methods have been extended to data
from GWAS to detect pathway association. Compared
to expression data, several distinctive features in the
data from GWAS require different methodological
* Correspondence: h.uh@lumc.nl
1Department of Medical Statistics and Bioinformatics, Leiden University
Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands
Full list of author information is available at the end of the article
Uh et al. BMC Proceedings 2011, 5(Suppl 9):S90
http://www.biomedcentral.com/1753-6561/5/S9/S90
© 2011 Uh et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.considerations. In contrast to gene expression data, in
which each gene contains one expression value, in data
from GWAS each gene contains many SNPs that are in
linkage disequilibrium (LD). Here lies the distinction
between one- and two-stage approaches; the first
approach ignores these biological features, and hence
the second approach might be more powerful [4]. Incor-
poration of LD information, however, might be less
essential if we focus on rare variants using sequencing
data because of weak correlation of rare variants with
common SNPs.
In this paper, using the data provided by Genetic Ana-
lysis Workshop 17 (GAW17) [5] and several pathway
analysis methods, we test the vascular endothelial
growth factor (VEGF) pathway that influences quantita-
tive trait Q1. Because we have a target gene set (we
knew the “answers” to the GAW17 simulation), the nat-
ural choice is the self-contained methods that consider
only the genes or SNPs involved in the specific gene set.
The first method to be applied is the global test (GT)
[6]; this test was designed for gene expression data and
uses all SNPs without consideration of gene-level effects
(one-stage approach). Next we consider two two-stage
approaches that were designed for detecting common
variants: the gene set ridge regression in association stu-
dies (GRASS) algorithm [4] and a new test called the
empirical Bayes (EB) method [7]. At the gene-level, the
GRASS algorithm uses LD information within a gene
using principal components analysis, and at the pathway
level the GRASS algorithm uses ridge regression. The
EB method uses a mixed-effects model with a general
random effects structure at the pathway level and uses
the empirical Bayes estimates of the random effects of
the first stage as covariates in the model for the pheno-
type. Because the GRASS algorithm can deal with only
binary outcome, the GAW17 affected-unaffected pheno-
type serves as the outcome variable for these analyses.
The methods we use were designed to detect multiple
common variants with small effects. To better deal with
the low frequency of rare variants, we propose to weight
counts of each rare variant (MAF < 1%) on the basis of
the estimated variance under the null hypothesis of no
association. We propose the weighted global test
(WGT), in which the weights are defined as in the
weighted-sum method [8] for rare variants and take a
value of 1 for common variants in the GT.
Once significant pathways are identified, we might
want to pinpoint the associated genes for further analy-
sis. We consider three methods at the gene level: the
combined multivariate and collapsing (CMC) method
[9], the weighted-sum approach [8] that analyzes only
rare variants, and the WGT. For details of the first two
methods, we refer to Dering et al. [10].
All programming has been conducted in R (http://
www.r-project.org). The R package globaltest can be
obtained at http://www.bioconductor.org, and the source
code for GRASS (SNPath) can be downloaded at http://
linchen.fhcrc.org/grass.html.
Methods
Study sample
We consider data from 697 unrelated individuals. We
analyze the 125 SNPs (28 common and 97 rare SNPs)
in 9 genes from the VEGF pathway, which influences
quantitative risk factor Q1. The MAFs range from 0.07%
to 16.5%. The dichotomous phenotype Affected serves
as the outcome variable (488 control subjects and 209
case subjects). We apply the pathway analysis methods
to the 200 simulated GAW17 data sets to study the
power.
Pathway analysis methods
We begin by establishing some notation. For N indivi-
duals at J loci, we let xi =( xi1, …, xiJ)′ be a column vec-
tor in which xij is the genotype at locus j in individual i.
We code each genotype as 0, 1, or 2, corresponding to
the number of minor alleles present at that locus. We
also let Yi denote the disease status of individual i,
which is coded 0 for control subjects and 1 for case sub-
jects. We then let X =( X1, …, XN)′ be an N × J matrix
of genotype data and let Y =( Y1, …, YN)′ be the N ×1
vector of disease status. In addition, for two-stage
approaches, we denote g =1 ,…, G for G genes in a
pathway.
The GT is a one-stage approach and is based on a
regression model that predicts response from the SNPs
of a gene set. We use generalized linear models to
model the dependency of response Y on gene expression
measurements X of a set of J SNPs on N samples:
hEY x ii j j
j
J
(( ) ) , ba b =+
= ∑
1
(1)
where h denotes the link function. Under an assump-
tion that all regression coefficients are sampled from a
common distribution with mean 0 and variance τ
2,
instead of testing H0: b =( b1, …, bJ)=0 ,o n ec a nt e s ta
new null hypothesis: H0: τ
2 = 0. Using the notation:
rx ii j j
j
=∑ b , (2)
the model simplifies to a random effects model:
EY r h r ii i () ( ) . =+
−1 a (3)
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score test statistic [11,12]:
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where R =( 1 / m)XX′, μ = h
−1(a), and μ2 is the second
central moment of Y under the null hypothesis . It can
be shown that Q is asymptotically normally distributed.
However, the p-value is calculated based on permuta-
tions of samples (case and control labels).
For the weighted version of the GT, the WGT, the
weights w =( w1, …, wJ)′ are added to the model as fol-
lows:
hEY
w
x i
j
ij j
j
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1
(5)
We assign more weight to rare variants (MAF < 1%),
as calculated in the weighted-sum approach, as follows
[8]. Let nj be the total number of subjects genotyped for
variant j, mj
U be the number of mutant alleles observed
in the control subjects, and n j
U be the total number of
individuals genotyped for variant j. The weight:
wn qq jj jj =− ⎡ ⎣ ⎤ ⎦ ()
/
1
12
(6)
is the expected variance based on allele frequencies qj
computed from control subjects only:
q
m
n
j
j
U
j
U =
+
+
1
22
. (7)
We assign the weight 1 to common SNPs.
The GRASS algorithm is a two-stage approach. At the
gene level the GRASS algorithm captures LD structure
with principal components analysis. For each gene, it
selects all nontrivial eigen-SNPs that explain about 95%
of the gene variation, and a least absolute shrinkage and
selection operator (LASSO) regression is used to sum-
marize the most representative eigen-SNPs:
  bb b gS S k =+ + () eigen-
2
eigen-
2
1
12 /
(8)
for k ≤ J eigen-SNPs. At the pathway level, the group
ridge regression is applied, and the statistic can be writ-
ten:
T G ==+ + ()    bb b 1
22 12 /
(9)
The significance of the statistic is determined by per-
mutation of case and control labels.
The EB method is a two-stage approach. In the first
step we summarize the subject-specific SNP information
using the EB estimates of the random effects of a
mixed-effects logistic regression. In the second stage,
the obtained EB estimates are used as covariates in the
phenotypic model to test for association of genes. For
details we refer to Houwing-Duistermaat et al. [7]. Let
Xigj be the genotype at locus j in gene g for individual i.
Let bi be the random effect for subject i,a n dl e tbig be
the random effect of gene g of individual i.U n d e r
Hardy-Weinberg equilibrium, Xigj given bi and big is
assumed to follow a binomial distribution with the num-
ber of trials being 2 and a probability πigj. The probabil-
ity is modeled as follows:
log
p
p
igj
igj
ii g bb
1−
=+ (10)
For each gene the EB estimate is given by:
eb b b ig i ig ˆˆ ˆ =+ (11)
Intuitively, the EB estimate can be interpreted as fol-
lows: The more minor alleles an individual has over all
the SNPs in a gene, the higher the EB estimate will be
for this gene.
Calculation of type I error rate and power
Because none of the methods have been applied to path-
way analysis with multiple common and rare variants, we
investigate the type I error rate and power of each
method. To determine the type I error rate, we simulate
phenotype under the null hypothesis of no association;
we generate 1,000 samples from the normal distribution
and dichotomize the phenotypes by taking the top 30%
as case subjects and the rest as control subjects. The type
I error rates of the methods are then calculated as the
proportion of significant replicates at the nominal level of
5% out of 1,000 replicates. For the type I error rate, 95%
of the empirical estimates of 1,000 replicates are expected
to fall between 0.036 and 0.064. The empirical power is
determined by calculating the number of times the P-
values are smaller than the preset threshold of 0.05
divided by 200, the number of simulated phenotypes.
Results
We first compared four pathway analysis methods: GT,
GRASS, the EB method, and WGT. These tests were
performed for 697 unrelated individuals, and the P-
values were obtained by analyzing functional and non-
functional SNPs (28 common SNPs and 97 rare SNPs in
9 genes). As shown in Table 1, type I error rates for all
methods were at the 5% level. The powers of the GT
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but the EB method had little power (5%) to establish
association. The WGT, in which rare variants received
more weight, as described in the Methods section, had
an increased power of 65%.
To narrow down the candidate region and possibly
pinpoint the associated genes for further analysis, we
conducted an association analysis of each gene in the
pathway. Because the WGT performed best at the path-
w a yl e v e l ,w ec o m p a r e dt h eW G Tt ot h eC M Ca n d
weighted-sum methods. In Table 2, the power of the
three methods at each gene is given. Nine genes influ-
ence the Q1 quantitative risk factor, but VEGFC,c o n -
taining only one rare SNP, was not analyzed. Except for
FLT1, the power of all three methods was low, and the
CMC method outperformed the other methods. For
FLT1,f o rw h i c hm o r er a r ev a r i a n t sw e r ei n c l u d e d ,t h e
two methods that assign more weight to rare variants
performed better.
Next we investigated whether the common variants
might tag rare variants. We first examined the correla-
tion between the SNPs. We used Haploview [13] to pro-
duce a LD plot using the r
2 measure. Figure 1 shows
weak correlations (r
2 ≈ 0) between the 125 SNPs. Then,
we examined the EB estimates, which reflect the
Table 1 Type I error rate and empirical power of tests for
125 SNPs in the VEGF pathway
Method Type I error rate Empirical power
Global test 0.044 0.41
GRASS 0.047 0.43
Empirical Bayes 0.055 0.05
Weighted global test 0.041 0.65
Table 2 Empirical power of tests for genes in the VEGF
pathway
Gene Number of SNPs Empirical power
Total Common Rare CMC Weighted-
sum
Weighted
global test
ARNT 18 (5) 3 (1) 15 (4) 0.31 0.28 0.12
ELAVL4 10 (2) 3 (0) 7 (2) 0.27 0.10 0.14
FLT1 35 (11) 10 (3) 25 (8) 0.80 0.83 0.84
FLT4 10 (2) 2 (0) 8 (2) 0.03 0.02 0.02
HIF1A 8 (4) 1 (1) 7 (3) 0.03 0.02 0.03
HIF3A 21 (3) 6 (0) 15 (3) 0.13 0.04 0.15
KDR 16 (10) 2 (2) 14 (8) 0.16 0.09 0.08
VEGFA 6 (1) 1 (0) 5 (1) 0.07 0.05 0.08
VEGFC 1 (1) 0 (0) 1 (1)
The number of functional SNPs is shown in parentheses.

Figure 1 Linkage disequilibrium of 125 SNPs using r
2 in the VEGF pathway. The low r
2 ≈ 0 values (white cells) show weak correlations
between the SNPs. The white cells indicate absence of LD (r
2 = 0), shades of grey intermediate degree of LD (0 <r
2 < 1), and black cells high
LD (r
2 = 1).
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(Figure 2). Overall, there was little evidence that com-
mon variants tagged rare ones. Otherwise, the EB esti-
mates of the subjects with rare variants (green circles)
would have had higher EB values to contribute to over-
all statistics. For FLT1 and KDR the contribution of sub-
jects with rare variants was comparable to the
contribution of subjects with common variants.
Discussion and conclusions
We investigated the performance of several pathway
analysis methods to detect multiple rare variants that
are associated with disease. The empirical power for all
methods was low. The powers of the GT and GRASS
algorithm were comparable, even though the GT did
not use gene-level information (such as LD in a gene
and the size of genes). As depicted in Figure 1, rare and
common SNPs were weakly correlated with each other.
Adding LD information, therefore, would not improve
efficiency. The GRASS algorithm uses principal compo-
nents analysis at the gene level, and the robustness of
the principal components analysis for summarizing rare
variants should be investigated. By giving more weight
to rare variants, the power of the WGT increased from
41% to 65%. Improvement by using a variable threshold
for rare variants or other methods might be possible.
The power of the EB method was poor, which implied
that the EB method cannot deal with rare variants well.
This was also confirmed by investigating the EB esti-
mates of individuals with rare variants (Figure 2). A lar-
ger number of common and rare variants within a gene
might improve the EB approach. Improvements might
also be possible by better summarizing the information
on rare variants at the gene level by collapsing rare var-
iants and including family data.
We also studied the type I error rate by using (200)
dichotomized Q4 phenotypes, because Q4 phenotypes
are assumed not to be associated with any SNP in the
VEGF pathway that influences Q1. This resulted in
extremely inflated type I error rates. To investigate pos-
sible correlation between dichotomized phenotypes Q4
and the Affected status, we constructed a simple 2 × 2
table. The concordance rates for 200 data sets were
68.2–75.9% with an average of 72.5%; that is, 72.5% of
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Figure 2 Empirical Bayes estimates of individuals per gene. The EB estimates were obtained using the EB approach in a gene-level analysis
and summarize the amount of information contained by each gene. Higher EB estimates indicate more information for the gene. The green
circles depict individuals with rare variants.
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Page 5 of 6subjects had the same case-control status in both phe-
notypes. Simulating phenotype under the null hypothesis
of no association seems a better practice for estimating
type I error rate.
Concerning the conjecture of whether pathway analy-
sis would be helpful for detecting multiple common and
rare variants jointly, both Figures 1 and 2 show little
evidence of common variants tagging rare ones. In Fig-
ure 1 we used the r
2 measure. If both of two loci have
rare alleles, it is possible for D′ to be 1 and r
2 to be
small. Hence, D′ is hard to interpret with rare alleles,
and we chose to use r
2, which is a better measure for
this situation. New methods might be needed to accom-
modate the specific features of the sequencing data.
When pinpointing specific genes, except FLT1,t h e
empirical power of all three methods was low. For FLT1
there were eight rare and three common causal variants;
the effect sizes of the common variants ranged from
0.61 to 0.74. In contrast, the power to detect KDR,
which has eight rare and two common variants and
roughly the same genetic profile as FLT1,w a sv e r yl o w .
Ap o s s i b l ee x p l a n a t i o nc o u l db et h a tt h ea m o u n to f
information contained in the two genes is different.
Here, the EB estimates at the gene level could be a use-
ful tool; in Figure 2 the median value of FLT1 was
higher than that of KDR. In addition, when common
and rare variants are analyzed together, the common
variants might play a significant role. The effect sizes of
the common variants in FLT1 (0.61–0.74) were larger
that those in KDR (0.14 and 0.30).
We investigated the use of pathway analysis methods
by jointly considering common and rare variants for
sequencing data. We report promising performance of
the WGT, which gives larger weights to rare variants
compared to other methods intended for detecting com-
mon variants. Our conclusion is that straightforward
application of pathway analysis is not satisfactory; hence,
when common and rare variants are jointly analyzed
using sequencing data, larger weights should be assigned
to rare variants.
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